01—Abstract
Summary
Summary of the 8-K filed October 22, 2026. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Incorporated (DGX) reported strong third quarter 2026 financial results, exceeding expectations and prompting an upward revision of its full-year 2026 guidance.
The company announced total revenues of $3.10 billiona, a 10.0% increase year-over-year, driven by robust organic revenue growth. Reported diluted EPS rose by 28.7% to $2.78, with adjusted diluted EPS growing 15.4% to $3.00.
This performance has led Quest Diagnostics to raise its full-year revenue guidance to a range of $12.065 billion to $12.105 billionb and its adjusted diluted EPS guidance to $11.25-$11.35. The company attributes its success to strong performance across physician, hospital, and consumer channels, augmented by efficiency gains from automation and AI, and highlighted strategic initiatives such as expanding its Alzheimer's diagnostic offerings and an integration with Apple Health.
02—Key points
Key Highlights
- Third quarter 2026 revenues reached $3.10 billion, up 10.0% year-over-year, fueled by strong organic revenue growth.
- Reported diluted EPS for Q3 2026 was $2.78, a significant increase of 28.7% compared to Q3 2025.
- Adjusted diluted EPS for Q3 2026 was $3.00, representing a 15.4% increase year-over-year.
- Full-year 2026 revenue guidance has been raised to $12.065 billion - $12.105 billion.
- Full-year 2026 adjusted diluted EPS guidance increased to $11.25 - $11.35.
- The company is expanding its Alzheimer's diagnostic capabilities with a new test panel including pTau217.
- Quest Diagnostics is integrating its services with Apple Health, allowing users to purchase tailored laboratory test panels.
- Capital expenditures are projected at approximately $550 million for the full year 2026, with cash provided by operations expected around $1.90 billion.
03—Questions
Frequently Asked Questions
What were the primary drivers of Quest Diagnostics' revenue growth in Q3 2026?
The primary drivers of revenue growth were strong organic revenue growth across its physician, hospital, and consumer channels, complemented by productivity gains from automation and AI. The company noted that its solutions are meeting the growing clinical care needs of an aging population and the increasing focus on prevention and wellness.
Why did Quest Diagnostics raise its full-year guidance?
Quest Diagnostics raised its full-year guidance due to its strong performance in the third quarter, characterized by significant revenue and adjusted EPS growth. Management expressed confidence in continued growth trends and operational performance.
What are the key strategic initiatives mentioned in the report?
Key strategic initiatives include the integration of laboratory testing purchases through the Apple Health app, the acquisition of select outreach lab assets in the Northeastern U.S., the expansion of its AD-Detect® menu for Alzheimer's disease diagnosis, and the advancement of Project Nova for Epic solutions deployment.
How does the company define 'adjusted' financial measures?
The company defines 'adjusted' non-GAAP operating performance measures as those that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits (ETB) associated with stock-based compensation, and gains/losses from strategic investments, among other items. These are presented to provide a clearer view of underlying business trends.
04—Continue